COMPANY ANNOUNCEMENT NO 56/2025 – November 12, 2025EBIT up 15% in Q3 driven by solid commercial performance and margin expansion Key Highlights Q3 2025Market share gains and solid commercial performance, driven by our long-term focus on growth categories Reported net revenue growth of 5.3% in Q3 (4.2% YTD) Solid margin expansion and EBIT growth of 15.1% in Q3 (12.6% YTD) Strong Q3 performance in our key Finnish market, following a soft Q2 due to cold weather Earnings per share increased by 20.4% in Q3, driven by stronger profitability Free cash flow increased by 9.5% in Q3 and continues to track in line with our plans We now expect to deliver full-year EBIT growth at the high end of the 8-12% rangeCEO Lars Jensen comments: “We delivered a strong third quarter with 15% EBIT growth, driven by solid margin expansion and...

– Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart for the treatment of atopic dermatitis submitted by Simcere, the Company’s exclusive licensee in Greater China, was accepted by China’s NMPA – – Completed termination of American Depositary Receipt program and directly listed our ordinary shares on Nasdaq – – Presented positive data at ERS 2025 supporting the potential of rademikibart to deliver differentiated efficacy and safety in patients across a broad range of baseline type 2 inflammatory markers – SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company...

Quarterly Revenue Up 49% Year-over-Year Positioned to Capitalize on Tape Storage Resurgence and Data Growth Megatrend Debt-Free, Profitable, and Uplisting-Ready with Expanding Strategic Opportunities CAMARILLO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Qualstar Corporation (OTC: QBAK), a trusted provider of scalable data storage and high-efficiency power solutions, today reported financial results for the third quarter ended September 30, 2025. The third quarter of 2025 reflected strong execution and accelerating demand for Qualstar’s tape-storage systems. With no debt, consistent profitability, and growing visibility across global customers and partners, Qualstar is well-positioned to scale both organically and through strategic initiatives as the data-storage industry enters a new era of growth. Third Quarter 2025 Financial HighlightsRevenue...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell lines, highlighting potential effectiveness against five KRAS-driven cancer types Successfully raised over $9 million during the third quarter, significantly strengthening the Company’s balance sheet Grand Cayman, Cayman Islands, Nov. 12, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on recent business developments. Recent Milestones & Business...

Third quarter 2025 revenue totaled approximately $18.7 million, an increase of 292% year-over-year and 62% sequentially Company is reiterating revenue guidance for 2026 of $225 million Conference call today at 5:00 p.m. ET BARTLETT, Tenn., Nov. 12, 2025 (GLOBE NEWSWIRE) — SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a wireless and fintech technology company connecting subprime and underserved consumers to essential mobile and financial services, today announced revenue growth of 292% year-over-year and 62% sequentially to $18.7 million for the third quarter ended September 30, 2025. The Company is reiterating revenue guidance of $225 million for 2026. “The 2025 third quarter represented an important inflection point for our multi-channel growth platform, which yielded revenue growth of 292% year-over-year and...

Cloud and SaaS revenue increased 9.4% compared with the prior year period, reflecting a continued shift toward recurring, platform-based offerings ENCINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, reported results for the fiscal first quarter of 2026 ended September 30, 2025. Fiscal First Quarter 2026 Financial Results Total net revenues for the first quarter of fiscal 2026 increased 2.8% to $15 million, compared with $14.6 million in the prior year period, driven by a 9.4% increase in subscription and support revenues. On a constant currency basis, total net revenues were $15.1 million.Total subscription (SaaS and Cloud) and support revenues increased...

Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first quarter delivered record quarterly revenue of $1.11 million, driven by accelerating cartridge sales, significant customer...

Updated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 34% overall response rate (ORR) observed among 103 evaluable patients across all cohorts with a median duration of response of 7.6 months 46% ORR observed among 48 evaluable patients in ovarian cancer cohort with a median duration of response of 8.0 months Rezatapopt New Drug Application submission for platinum resistant/refractory ovarian cancer planned in first quarter of 2027 Cash, cash equivalents, and marketable securities of $129.3 million as of September 30, 2025, providing expected cash runway to end of first quarter of 2027PRINCETON, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) — PMV Pharmaceuticals,...

Presented robust CRB-701 clinical data at ESMO 2025 – 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUC CRB-701 HNSCC registrational study planned to start mid-2026 Completed $75 million public offering, extending cash runway into 2028 Expected to complete CRB-913 SAD/MAD study and initiate Ph1b study in obese patients in Q4 2025NORWOOD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported financial results for the quarter ended September 30, 2025. “This has been a productive period for Corbus, led by the presentation of CRB-701 data at ESMO 2025,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We are encouraged...

Encouraging Clinical Progress, Including Positive Interim Phase 2 Results for the Treatment of Cancer Anorexia Cachexia Syndrome SOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended September 30, 2025. “We continue to deliver on our clinical and strategic objectives, advancing three differentiated programs with strong potential to address large, underserved markets,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “We were very pleased with the interim Phase...